A healthcare worker prepares a dose of the AstraZeneca vaccine against the coronavirus disease during a vaccination rollout for teachers in Ronda, Spain February 25, 2021. — Reuters picFRANKFURT, March 22 — The Covid-19 vaccine developed by Oxford University and AstraZeneca was 79 per cent effective in preventing symptomatic illness a large trial in the United States, Chile and Peru, the company said on Monday, paving the way for it to apply for US approval.
The data will give credence to the British shot after results from earlier, separate late-stage studies raised questions about the robustness of the data. After briefly halting its use, many European countries have resumed using the shot in their inoculation programmes after a regional regulator said it was safe, while several country leaders are also taking the vaccine to boost confidence.